Phylogica tech reviewed in journal
13 February, 2006 by Helen SchullerA review of Perth-based Phylogica's (ASX:PYC) Phylomer technology has been published in the February issue of Nature Biotechnology.
BrainZ expands US operations
10 February, 2006 by Helen SchullerAuckland-based BrainZ (ASX:BZI) has established its US clinical support team and headquarters.
DotScan helps join the dots in identifying heart disease
09 February, 2006 by Graeme O'NeillUniversity of Sydney researchers claim to have achieved almost perfect discrimination between two major forms of heart disease from patients' blood samples, using Sydney firm Medsaic's proprietary DotScan technology.
Prana completes Alzheimer's phase I
07 February, 2006 by Helen SchullerMelbourne's Prana Biotechnology (ASX:PBT, Nasdaq:PRAN) has successfully completed a second phase I trial of its lead compound PBT2, under development as a therapy for Alzheimer's disease.
Reshaped Australian healthcare firms hold promise
06 February, 2006 by Sonali PaulMost of Australia's leading healthcare firms are expected to post strong first-half profit growth and provide positive outlook statements as the benefits of takeovers and spin-offs start to filter through, according to analysts.
UQ team links vitamin D deficiency with schizophrenia, MS
06 February, 2006 by Graeme O'NeillScientists at the University of Queensland have linked maternal vitamin D deficiency in pregnancy to abnormal foetal brain development and an increased the risk of behavioural problems, schizophrenia and multiple sclerosis (MS) later in life.
CyGenics joins international cancer collaboration
03 February, 2006 by Helen SchullerCell therapy company CyGenics (ASX:CYN) will be part of a new international collaborative effort to develop new treatments of cancer using the novel approach of developing and mobilising immune cells outside the human body.
Prima publishes cancer trial results, outlines road ahead
02 February, 2006 by Helen SchullerPrima Biomed's (ASX:PRR) results from a phase I clinical trial of its CancerVac MFP technology for advanced adenocarcinoma have been accepted and published in the journal Clinical Cancer Research.
Giaconda touts results for H. Pylori, Crohn's disease
31 January, 2006 by Helen SchullerSydney-based Giaconda (ASX:GIA) has reported positive results from phase II trials of two of its compounds, Heliconda for Helicobacter pylori infection and Myoconda for Crohn's disease.
Benitec delays HIV/AIDS drug IND filing
31 January, 2006 by Ruth BeranGene therapy company Benitec's (ASX:BLT) shares fell on news that the US FDA investigational new drug (IND) filing for its HIV/AIDS therapeutic will be delayed.
Zenyth licence to boost antibody targets
30 January, 2006 by Graeme O'NeillZenyth Therapeutics (ASX:ZTL), formerly Amrad, has taken a licence from Massachusetts-based Dyax Corp, to use the US company's proprietary phage display libraries to develop antibody therapeutics for inflammation and cancer.
Tissue Therapies to repeat animal trial
27 January, 2006 by Helen SchullerBrisbane biotech Tissue Therapies (ASX:TIS) will repeat an animal trial designed to gather data to optimise its wound treatment VitroGro for human clinical trials following independent review of the results.
Ian Frazer named Australian of the Year
26 January, 2006 by Staff WritersProf Ian Frazer, inventor of the world's first cancer vaccine, Gardasil, has been named Australian of the Year.
Apollo completes phase Ib psoriasis trial data collection
24 January, 2006 by Helen SchullerSydney-based biopharma Apollo Life Sciences (ASX:AOP) said no significant adverse side-effects were detected in a phase Ib trial of its topical psoriasis cream, developed from human-expressed protein.
BioPharmica touts new cancer target
18 January, 2006 by Graeme O'NeillNewly listed Perth meditech BioPharmica (ASX:BPH) has taken the wraps off a new tumour-suppressor gene candidate that shows high promise as a therapeutic and diagnostic target for many cancers, as well as in AIDS and the brain disorder Huntington's disease.
